Carboxyamidotriazole in Treating Patients With Metastatic Kidney Cancer
Completed · Phase 2 · Has a placebo group
Conditions studied: Recurrent Renal Cell Cancer, Stage IV Renal Cell Cancer
In brief
Randomized phase II trial to study the effectiveness of carboxyamidotriazole in treating patients who have metastatic kidney cancer. Carboxyamidotriazole may stop the growth of kidney cancer by stopping blood flow to the tumor
Key facts
- Study ID
- NCT00006486
- Run by
- National Cancer Institute (NCI)
- People needed
- 335
- Starts
- 2000-10-01
- Last updated by the study team
- 2013-01-16
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Histologically confirmed renal cell carcinoma
- Metastatic or unresectable disease
- Documented disease progression, even after nephrectomy
- At least 1 unidimensionally measurable lesion
- At least 20 mm by conventional techniques
- At least 10 mm by spiral CT scan
- The following lesions are not considered measurable:
- Bone lesions
- Leptomeningeal disease
- Ascites
- Pleural/pericardial effusion
- Abdominal masses not confirmed and followed by imaging
- Cystic lesions
- Performance status - CTC 0-2
- WBC at least 2,000/mm\^3
- Platelet count at least 75,000/mm\^3
- Bilirubin no greater than upper limit of normal (ULN)
- AST no greater than 2.5 times ULN
- Creatinine no greater than 2.0 mg/dL
- Not pregnant or nursing
- Fertile patients must use effective contraception
- No baseline neuropathy or cerebellar dysfunction greater than grade 1
- At least 4 weeks since prior immunotherapy
- No prior carboxyamidotriazole
- No concurrent filgrastim (G-CSF) or sargramostim (GM-CSF)
Where it is running
- Cancer and Leukemia Group B — Chicago, Illinois, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.